Distinct roles of β-Cell mass and function during type 1 diabetes onset and remission

Diabetes

Volumn 64, Issue 6, 2015, Pages 2148-2160

  Chmelova, Helena ^a,b   Cohrs, Christian M ^a,b   Chouinard, Julie A ^a,b   Petzold, Cathleen ^a   Kuhn, Matthias ^b   Chen, Chunguang ^a,b   Roeder, Ingo ^b   Kretschmer, Karsten ^a,b   Speier, Stephan ^a,b  

^a CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; ARTICLE; AUTOIMMUNE DISEASE; CELL DENSITY; CELL EXPANSION; CELL INFILTRATION; CELL STRUCTURE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; LONGITUDINAL STUDY; MALE; MASS; MOLECULAR IMAGING; MOUSE; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; REMISSION; ANIMAL; METABOLISM; PATHOLOGY;

ANIMALS; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPERGLYCEMIA; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MALE; MICE;

EID: 84940105815     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1055     Document Type: Article

References (46)

1. Steffes MW, Sibley S, Jackson M, Thomas W. b-Cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003;26:832-836.
2. Foulis AK, Liddle CN, Farquharson MA, Richmond JA, Weir RS. The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus: A 25- year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia 1986;29:267-274.
3. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 1965;14:619-633.
4. Kolb H, Gale EA. Does partial preservation of residual beta-cell function justify immune intervention in recent onset type I diabetes? Diabetologia 2001; 44:1349-1353.
5. Karjalainen J, Salmela P, Ilonen J, Surcel HM, Knip M. A comparison of childhood and adult type I diabetes mellitus. N Engl J Med 1989;320:881- 886.
6. Klinke DJ 2nd. Extent of beta cell destruction is important but insufficient to predict the onset of type 1 diabetes mellitus. PLoS One 2008;3:e1374.
7. Steele C, Hagopian WA, Gitelman S, et al. Insulin secretion in type 1 diabetes. Diabetes 2004;53:426-433.
8. Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia 2005;48:2221-2228.
9. Keenan HA, Sun JK, Levine J, et al. Residual insulin production and pancreatic b-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 2010;59:2846-2853.
10. Jackson RL, Boyd JD, Smith TE. Stabilization of the diabetic child. Am J Dis Child 1940;59:332-341.
11. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Evidence of increased islet cell proliferation in patients with recent-onset type 1 diabetes. Diabetologia 2010;53:2020-2028.
12. Speier S, Nyqvist D, Cabrera O, et al. Noninvasive in vivo imaging of pancreatic islet cell biology. Nat Med 2008;14:574-578.
13. Speier S, Nyqvist D, Köhler M, Caicedo A, Leibiger IB, Berggren PO. Noninvasive high-resolution in vivo imaging of cell biology in the anterior chamber of the mouse eye. Nat Protoc 2008;3:1278-1286.
14. Luo X, Herold KC, Miller SD. Immunotherapy of type 1 diabetes: Where are we and where should we be going? Immunity 2010;32:488-499.
15. Lo D, Freedman J, Hesse S, Palmiter RD, Brinster RL, Sherman LA. Peripheral tolerance to an islet cell-specific hemagglutinin transgene affects both CD4+ and CD8+ T cells. Eur J Immunol 1992;22:1013-1022.
16. Hara M, Wang X, Kawamura T, et al. Transgenic mice with green fluorescent protein-labeled pancreatic beta -cells. Am J Physiol Endocrinol Metab 2003;284:E177-E183.
17. Postic C, Shiota M, Niswender KD, et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cellspecific gene knock-outs using Cre recombinase. J Biol Chem 1999;274: 305-315.
18. Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L. A global doublefluorescent Cre reporter mouse. Genesis 2007;45:593-605.
19. Sarukhan A, Lanoue A, Franzke A, Brousse N, Buer J, von Boehmer H. Changes in function of antigen-specific lymphocytes correlating with progression towards diabetes in a transgenic model. EMBO J 1998;17:71-80.
20. Petzold C, Riewaldt J, Watts D, Sparwasser T, Schallenberg S, Kretschmer K. Foxp3(+) regulatory T cells in mouse models of type 1 diabetes. J Diabetes Res 2013;2013:940710.
21. Borg DJ, Weigelt M, Wilhelm C, et al. Mesenchymal stromal cells improve transplanted islet survival and islet function in a syngeneic mouse model. Diabetologia 2014;57:522-531.
22. Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: An open-source platform for biological-image analysis. Nat Methods 2012;9:676-682.
23. Ilegems E, Dicker A, Speier S, et al. Reporter islets in the eye reveal the plasticity of the endocrine pancreas. Proc Natl Acad Sci U S A 2013;110:20581- 20586.
24. Rodriguez-Diaz R, Speier S, Molano RD, et al. Noninvasive in vivo model demonstrating the effects of autonomic innervation on pancreatic islet function. Proc Natl Acad Sci U S A 2012;109:21456-21461.
25. Miska J, Abdulreda MH, Devarajan P, et al. Real- Time immune cell interactions in target tissue during autoimmune-induced damage and graft tolerance. J Exp Med 2014;211:441-456.
26. Katsuta H, Aguayo-Mazzucato C, Katsuta R, et al. Subpopulations of GFP marked mouse pancreatic b-cells differ in size, granularity, and insulin secretion. Endocrinology 2012;153:5180-5187.
27. Nielsen DA, Lernmark A, Berelowitz M, Bloom GD, Steiner DF. Sorting of pancreatic islet cell subpopulations by light scattering using a fluorescenceactivated cell sorter. Diabetes 1982;31:299-306.
28. Pechhold K, Zhu X, Harrison VS, et al. Dynamic changes in pancreatic endocrine cell abundance, distribution, and function in antigen-induced and spontaneous autoimmune diabetes. Diabetes 2009;58:1175-1184.
29. Bosco D, Armanet M, Morel P, et al. Unique arrangement of a- And b-cells in human islets of Langerhans. Diabetes 2010;59:1202-1210.
30. Sarukhan A, Garcia C, Lanoue A, von Boehmer H. Allelic inclusion of T cell receptor alpha genes poses an autoimmune hazard due to low-level expression of autospecific receptors. Immunity 1998;8:563-570.
31. Sreenan S, Pick AJ, Levisetti M, Baldwin AC, Pugh W, Polonsky KS. Increased b-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. Diabetes 1999;48:989-996.
32. Haskins K, Portas M, Bergman B, Lafferty K, Bradley B. Pancreatic isletspecific T-cell clones from nonobese diabetic mice. Proc Natl Acad Sci U S A 1989;86:8000-8004.
33. Pechhold K, Koczwara K, Zhu X, et al. Blood glucose levels regulate pancreatic beta-cell proliferation during experimentally-induced and spontaneous autoimmune diabetes in mice. Plos One 2009;4:e4827.
34. Bonner-Weir S, Deery D, Leahy JL, Weir GC. Compensatory growth of pancreatic b-cells in adult rats after short- Term glucose infusion. Diabetes 1989; 38:49-53.
35. Porat S, Weinberg-Corem N, Tornovsky-Babaey S, et al. Control of pancreatic b cell regeneration by glucose metabolism. Cell Metab 2011;13: 440-449.
36. Diiorio P, Jurczyk A, Yang C, et al. Hyperglycemia-induced proliferation of adult human beta cells engrafted into spontaneously diabetic immunodeficient NOD-Rag1null IL2rgnull Ins2Akita mice. Pancreas 2011;40:1147- 1149.
37. Levitt HE, Cyphert TJ, Pascoe JL, et al. Glucose stimulates human beta cell replication in vivo in islets transplanted into NOD-severe combined immunodeficiency (SCID) mice. Diabetologia 2011;54:572-582.
38. Rankin MM, Kushner JA. Adaptive b-cell proliferation is severely restricted with advanced age. Diabetes 2009;58:1365-1372.
39. Block MB, Rosenfield RL, Mako ME, Steiner DF, Rubenstein AH. Sequential changes in beta-cell function in insulin- Treated diabetic patients assessed by C-peptide immunoreactivity. N Engl J Med 1973;288:1144-1148.
40. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces longterm remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A 1994;91:123-127.
41. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54:1763-1769.
42. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-1698.
43. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3- Antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352: 2598-2608.
44. Sherry NA, Kushner JA, Glandt M, Kitamura T, Brillantes AM, Herold KC. Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes. Diabetes 2006;55:3238-3245.
45. Hagopian W, Ferry RJ Jr, Sherry N, et al.; Protégé Trial Investigators. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: Two-year results from the randomized, placebo-controlled Protégé trial. Diabetes 2013;62:3901-3908.
46. Herold KC, Gitelman SE, Ehlers MR, et al.; AbATE Study Team. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with newonset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013;62: 3766-3774.